Lycia Therapeutics raised an oversubscribed $75 million Series D to move two lysosomal-targeting protein degraders into the clinic, giving oncology drug-discovery watchers a fresh financing signal around targeted degradation platforms. The company said the funds will support LCA-0061, which depletes IgE, and LCA-0321, which selectively depletes TSH receptor autoantibodies, with Eli Lilly among participating investors.

Why It Matters To Oncology

• Lycia is advancing LYTAC and cataLYTAC degraders, extending the protein degradation playbook beyond intracellular targets and into extracellular and membrane-associated disease drivers.

• For oncology clinicians following drug discovery, the raise underscores continued investor appetite for next-generation degrader modalities even outside cancer, with potential platform read-through for tumor targets that are hard to drug with conventional small molecules.

• The company's scientific roots also stand out: Lycia was co-founded by Nobel laureate Carolyn Bertozzi, a prominent figure in targeted protein degradation and chemical biology.

The Financials

• The Series D brought in $75 million and was described as oversubscribed.

• The round was co-led by Janus Henderson Investors and Balyasny Asset Management.

• Other backers included Adage Capital Management, HBM Healthcare Investments, OrbiMed, Lilly, Franklin Templeton, Invus, RTW Investments and Venrock Healthcare Capital Partners.

• Lycia previously emerged from stealth in 2020 with $50 million and later raised a $106.6 million Series C in 2024.

What They're Saying

• Lycia said the new capital will be used to advance its two lead programs into the clinic.

• LCA-0061 is being developed for food allergy and other allergic diseases, while LCA-0321 is aimed at Graves' disease by depleting pathogenic autoantibodies.

• Lilly had already validated interest in the platform through a 2021 discovery deal before joining the company's later financing rounds.

What's Next

• Key near-term milestones will be IND-enabling progress and first-in-human entry for both lead degraders.

• For oncology audiences, the bigger watchpoint is whether Lycia's lysosomal degradation approach can generate clinically meaningful selectivity, durability and safety that could support future expansion into cancer-relevant targets.

• Additional partnering interest could follow if early clinical data support the platform's ability to degrade targets beyond the reach of existing approaches.